Gilead Sciences, Inc.
A biopharmaceutical company making medicines for HIV, liver disease, and cancer, Gilead's products include HIV treatments like Biktarvy and Descovy, liver therapies Epclusa and Livdelzi, and CAR T-cell cancer therapies Yescarta and Tecartus. Founded in 1987 in Foster City, California, it was originally named Oligogen before being renamed after the "Balm of Gilead," an ancient healing resin mentioned in the Bible—a nod its founder picked up from a play he read in medical school.
Granted 6.50M · Sold 3.99M
Granted 17.95M · Bought 10.0K · Sold 15.94M
Granted 1.01M · Sold 110.8K
Granted 6.32M · Sold 4.93M
Granted 332.6K · Sold 202.8K
Granted 1.71M · Sold 366.3K
Granted 1.20M · Sold 837.5K
Granted 1.21M · Sold 766.8K
Granted 994.6K · Sold 618.4K
Granted 99.0K · Sold 80.0K
Granted 192.2K · Sold 175.0K
Granted 522.5K · Sold 407.5K
Granted 578.2K · Sold 244.1K
Granted 77.9K · Bought 42.8K · Sold 46.9K
Granted 134.1K · Sold 3.5K
Granted 447.5K · Sold 250.1K
Granted 112.9K · Sold 53.6K
Granted 449.0K · Sold 354.7K
Granted 165.1K · Sold 162.4K
Granted 497.7K · Sold 537.7K
Granted 2.84M · Sold 2.65M
Granted 492.2K · Sold 454.2K
Granted 86.8K · Sold 48.5K
Granted 21.1K
Granted 22.9K · Bought 2.6K
Granted 603.4K · Sold 584.5K
Granted 23.0K
Granted 191.2K · Sold 137.8K
Granted 151.9K · Sold 115.1K
Granted 13.9K
Granted 1.59M · Sold 1.39M
Granted 410.1K · Sold 374.5K
Granted 27.5K
Granted 378.7K · Sold 354.0K
Granted 18.0K
Granted 14.0K
Granted 13.4K · Sold 189
Granted 30.9K · Sold 18.0K
Granted 452.1K · Sold 443.8K
Granted 36.9K · Sold 26.8K
Granted 9.8K
Granted 6.3K
Granted 2.3K
Granted 5.5K
Granted 7.0K · Sold 5.6K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Bischofberger Norbert WEVP, R&D and CSO · 358 transactions | — | 4.66Mas of Feb 2018 | 6.50M | — | 3.99M |
| Martin John CDirector · 642 transactions | — | 2.90Mas of Feb 2019 | 17.95M | 10.0K | 15.94M |
| Moore Gordon EarleDirector · 15 transactions | — | 1.62Mas of Aug 2012 | 1.01M | — | 110.8K |
| Milligan John FPresident and CEO, Director · 299 transactions | — | 1.57Mas of Nov 2018 | 6.32M | — | 4.93M |
| Davignon EtienneDirector · 29 transactions | — | 839.1Kas of May 2016 | 332.6K | — | 202.8K |
| O'Day Daniel PatrickChairman & CEO, Director · 98 transactions | — | 626.3K | 1.71M | — | 366.3K |
| Denny James MDirector · 297 transactions | — | 589.2Kas of Dec 2012 | 1.20M | — | 837.5K |
| Washington Robin LEVP, CFO · 225 transactions | — | 277.6Kas of Feb 2019 | 1.21M | — | 766.8K |
| Dickinson Andrew DChief Financial Officer · 137 transactions | — | 171.6K | 994.6K | — | 618.4K |
| Yang TaiyinSVP, Pharm Dev & Mfg · 38 transactions | — | 155.0Kas of May 2007 | 99.0K | — | 80.0K |
| Meyers James REVP Worldwide Commercial Ops · 51 transactions | — | 142.8Kas of Feb 2018 | 192.2K | — | 175.0K |
| Wilson Gayle EDirector · 126 transactions | — | 129.1Kas of May 2020 | 522.5K | — | 407.5K |
| Mercier JohannaChief Comm & Corp Aff Officer · 110 transactions | — | 124.7K | 578.2K | — | 244.1K |
| Wold Olsen PerDirector · 25 transactions | — | 102.1Kas of May 2021 | 77.9K | 42.8K | 46.9K |
| Lofton Kevin EDirector · 21 transactions | — | 101.1Kas of May 2023 | 134.1K | — | 3.5K |
| Parsey MerdadChief Medical Officer · 71 transactions | — | 84.6Kas of Dec 2024 | 447.5K | — | 250.1K |
| Telman Deborah HEVP, Corporate Affairs & GC · 46 transactions | — | 79.6K | 112.9K | — | 53.6K |
| Carter Paul RutherfordEVP Commercial Ops · 122 transactions | — | 64.1Kas of Aug 2016 | 449.0K | — | 354.7K |
| Toole John JSVP, Clinical Research · 74 transactions | — | 63.7Kas of Apr 2007 | 165.1K | — | 162.4K |
| Lee William ASVP, Research · 127 transactions | — | 58.7Kas of May 2007 | 497.7K | — | 537.7K |
| Alton Gregg HChief Patient Officer · 754 transactions | — | 58.0Kas of Feb 2019 | 2.84M | — | 2.65M |
| Cogan John FrancisDirector · 115 transactions | — | 57.3Kas of May 2020 | 492.2K | — | 454.2K |
| Wilfong Diane E.Interim Corp Controller & CAO · 56 transactions | — | 46.6K | 86.8K | — | 48.5K |
| Patterson SandraSVP, Controllership · 30 transactions | — | 40.1Kas of Mar 2025 | 21.1K | — | — |
| Hills Carla ADirector · 9 transactions | — | 39.3Kas of May 2016 | 22.9K | 2.6K | — |
| Berg PaulDirector · 306 transactions | — | 36.9Kas of May 2011 | 603.4K | — | 584.5K |
| McHutchison John GChief Scientific Off/HeadR&D · 7 transactions | — | 35.2Kas of Feb 2019 | 23.0K | — | — |
| Pletcher Brett AEVP,Corp Affairs & Gen Counsel · 74 transactions | — | 33.7Kas of Jun 2022 | 191.2K | — | 137.8K |
| Whitley Richard JamesDirector · 51 transactions | — | 33.1Kas of May 2021 | 151.9K | — | 115.1K |
| Barton Jacqueline KDirector · 8 transactions | — | 27.2K | 13.9K | — | — |
| Young KevinChief Operating Officer · 173 transactions | — | 25.6Kas of Feb 2018 | 1.59M | — | 1.39M |
| Metza KristenSVP, Human Resources · 101 transactions | — | 25.3Kas of Nov 2012 | 410.1K | — | 374.5K |
| Berger DietmarChief Medical Officer · 7 transactions | — | 19.5K | 27.5K | — | — |
| Madigan John WDirector · 15 transactions | — | 18.5Kas of May 2017 | 378.7K | — | 354.0K |
| Manwani HarishDirector · 17 transactions | — | 15.0K | 18.0K | — | — |
| Montgomery Alan BruceSVP, Respiratory Therapeutics · 1 transaction | — | 14.7Kas of Sep 2006 | 14.0K | — | — |
| Rodriguez JavierDirector · 8 transactions | — | 13.4K | 13.4K | — | 189 |
| Welters AnthonyDirector · 13 transactions | — | 12.9K | 30.9K | — | 18.0K |
| Moore Nicholas GDirector · 92 transactions | — | 12.2Kas of Mar 2018 | 452.1K | — | 443.8K |
| Bluestone JeffreyDirector · 23 transactions | — | 10.1K | 36.9K | — | 26.8K |
| Hamill LauraEVP, Worldwide Commercial Ops · 2 transactions | — | 9.8Kas of May 2019 | 9.8K | — | — |
| Horning SandraDirector · 5 transactions | — | 6.3K | 6.3K | — | — |
| Cain Wettan Keeley MEVP Gen Counsel, Legal & Comp · 5 transactions | — | 5.6K | 2.3K | — | — |
| Love Ted WDirector · 4 transactions | — | 5.5K | 5.5K | — | — |
| Kramer Kelly A.Director · 5 transactions | — | 4.1K | 7.0K | — | 5.6K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: -36.63M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.